Isturisa (Osilodrostat)

Osilodrostat blocks the adrenal enzyme 11β‑hydroxylase (CYP11B1), which is essential for the final step of cortisol synthesis. Inhibition of this enzyme decreases the conversion of precursors to cortisol, thereby lowering circulating cortisol levels.

The dose of Isturisa is individualized and set by the prescribing clinician based on the patient’s cortisol levels, clinical response, and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of osilodrostat in pregnancy and lactation has not been established. It should be avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Isturisa, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isturisa (osilodrostat) is a potent 11β‑hydroxylase inhibitor, offering rapid cortisol reduction. Compared with ketoconazole, which has broader enzyme inhibition, osilodrostat provides more specific targeting with a different side‑effect profile, while metyrapone acts earlier in the steroidogenesis pathway.

Isturisa tablets should be stored at temperatures below 25 °C in their original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Isturisa is taken orally as a tablet, with or without food, according to the prescriber’s dosing schedule. Swallow the tablet whole with water; do not crush or chew unless specifically instructed by a healthcare professional.

The most serious risks include adrenal crisis due to over‑suppression of cortisol, severe hypokalemia, and potential liver injury. Patients should be monitored regularly for signs of these conditions and instructed to seek immediate medical attention if they occur.

Isturisa should not be used by individuals with known hypersensitivity to osilodrostat, severe hepatic impairment, or during pregnancy unless the benefit outweighs the risk. Patients with uncontrolled hypertension or significant electrolyte disturbances should be evaluated carefully before starting therapy.